![Kindle app logo image](https://m.media-amazon.com/images/G/31/kindle/app/kindle-app-logo._CB666540017_.png)
Download the free Kindle app and start reading Kindle books instantly on your smartphone, tablet or computer – no Kindle device required.
Read instantly on your browser with Kindle for Web.
Using your mobile phone camera, scan the code below and download the Kindle app.
The Creation of Psychopharmacology Paperback – 15 September 2004
Save Extra with 3 offers
10 days Replacement
Replacement Reason | Replacement Period | Replacement Policy |
---|---|---|
Defective, Wrong and Missing Item, Physical Damage | 10 days from delivery | Replacement |
Replacement Instructions
![](https://m.media-amazon.com/images/I/11Sa2OpQXzL.png)
Read full returns policy
Purchase options and add-ons
- Print length480 pages
- LanguageEnglish
- PublisherHarvard University Press
- Publication date15 September 2004
- Dimensions15.24 x 2.86 x 22.86 cm
- ISBN-100674015991
- ISBN-13978-0674015999
Product description
Review
[T]his sweeping history of medicine used to treat mental illness takes on the psychiatric and medical establishment...Healy does groundbreaking work...The Creation of Psychopharmacology details how psychiatric medication intersects with academic squabbles and popular culture. -- Janice Paskey ― Chronicle of Higher Education
David Healy is a respected historian of psychiatry who has written a book that should spark a major debate. He identifies current trends towards the abandonment of independent research into treatments for mental illness, the demand for Randomised Control Trials as the only acceptable measure of whether a treatment works, and the chilling control pharmaceutical companies now exert over psychiatry...This is an important and thought-provoking book...Healy's warning that, without a debate, we may be moving into an era when cosmetic psychiatry will be the new liposuction is worth heeding. -- Julie Wheelwright ― The Independent
This book is a good place to start if you want to get an overview of the role of drugs in the treatment of mental illness...[Healy] capture[s] an important current dilemma. -- Richard Restak ― Washington Times
Psychiatrists and historians owe a debt to David Healy. Over the years he has conducted interviews with all the leading figures in psychopharmacology...Drawing on these interviews and his wide reading of the scholarly literature, Healy has now constructed a subtle and compelling narrative of the development of psychotropic drugs...Healy ambitiously relates the emergence of drugs to the wider culture and shows how the two have interacted...[He] has written a highly stimulating and original book, which is brimful of ideas and deserves to be read and debated throughout the psychiatric community and beyond. -- Allan Beveridge ― British Journal of Psychiatry
[N]o one has described it more thoroughly, or elucidated the critical intersections between psychiatry and the pharmaceutical industry more clearly. -- Morgan T. Sammons ― Contemporary Psychology
About the Author
Product details
- Publisher : Harvard University Press; Revised ed. edition (15 September 2004)
- Language : English
- Paperback : 480 pages
- ISBN-10 : 0674015991
- ISBN-13 : 978-0674015999
- Item Weight : 590 g
- Dimensions : 15.24 x 2.86 x 22.86 cm
- Customer Reviews:
About the author
![David Healy](https://m.media-amazon.com/images/I/B1fl9lSG7QS._SY600_.jpg)
David Healy, born in Dublin, is a Professor of Psychiatry in McMaster University Canada, previously in Bangor and Cardiff Universities in Wales, UK.
He happened to be in the right/wrong place when the SSRI antidepressants came along bringing in their wake suicides, homicides, sexual dysfunction, birth defects and other problems - all initially hidden by a lack of access to research data, by ghostwriters and the hypnotisability of doctors. He had the good fortune to be surrounded by colleagues who got stuck into nailing down what is happening to medicine and after the setting up of RxISK.org in 2012 to find that there were a great many people who had been injured by treatment who were better at medical research than he was.
His work on the history of physical treatments in medicine and the adverse effects of treatment in based on interviews with key players in developing our current treatments and well as those who have been harmed by them
Customer reviews
- 5 star4 star3 star2 star1 star5 star100%0%0%0%0%100%
- 5 star4 star3 star2 star1 star4 star100%0%0%0%0%0%
- 5 star4 star3 star2 star1 star3 star100%0%0%0%0%0%
- 5 star4 star3 star2 star1 star2 star100%0%0%0%0%0%
- 5 star4 star3 star2 star1 star1 star100%0%0%0%0%0%
Top reviews from other countries
![](https://images-na.ssl-images-amazon.com/images/S/amazon-avatars-global/default._CR0,0,1024,1024_SX48_.png)
Perhaps Healy's most important point is that while industry (in this case big pharmaceuticals) will aim to provide a product that will alleviate or control psychiatric symptoms, their goal first and foremost is to create a larger profit margin. Thus, being accountable to shareholders, rather than the universities or clinicians that they have increasingly funded, "big pharma" acts in ways that often run counter to what the ostensible goal of psychiatry has been over the past one hundred years, i.e. finding pathologies and cures for mental illnesses.
Healy brilliantly shows how as the pharmaceutical industry grew in size and influence, the tacit goal became not to find a specific cure for specific illnesses, but to market drugs that were effective across a wide range of disorders to sell more product. Perhaps the most insidious part of the story is that in doing so, big pharmaceuticals devised ways to co-opt psychiatrists and university departments in order to define "new" illnesses of dubious character that they could then provide a fix for. ADHD stands out as one of the "star" illnesses that was, based on Healy's persuasive and varied evidence, created by companies. By controlling the evidence, and in many cases using ghost-written studies, they have been able to act within the FDA regulations while ignoring more effective medications simply because they are *too* specific and therefore less profitable.
The second main thread in Healy's narrative revolves around how psychopharmacology has over the past forty to fifty years been involved in the creation of a "biomedical self." Healy argues, quite persuasively, that as well as the 1960s being an era of liberation, it also created a more muddy definition of "health." Healy makes a strong point that as cosmetic pharmacology and surgeries have developed, it has been more difficult to define what illness is, and perhaps most importantly, our sense of self is tied directly to health matters and now largely defined by biomedical corporations.
Healy's work is an important one. It is far more than simply a "whistleblower's" account. This book provides an eye-opening history of how psychopharmacology in the early twenty first century is no longer in the hands of clinicians and researchers, but rather the companies that fund them. Perhaps the most ironic part of this history is that as health matters have become increasingly more technological and therefore more expensive, universities and other funding bodies that formerly controlled the flow of research and science no longer have the funds to do so. Thus, mental health matters are left in the hands of those who have profit concerns at the forefront of their minds and curing illness somewhere in back, if it is there at all.
For anyone who has ever been prescribed a medication, whether psychiatric or not, this book is a cautionary tale that not only asks the reader to question what is happening with big pharmaceuticals, but also asks us to look in the mirror and ask ourselves how much we have bought in (both figuratively and literally) to the biomedical self that has been defined for us.
![](https://images-na.ssl-images-amazon.com/images/S/amazon-avatars-global/default._CR0,0,1024,1024_SX48_.png)